Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SAB4700771

Sigma-Aldrich

Monoclonal Anti-HIV protease antibody produced in mouse

clone 1696, purified immunoglobulin, buffered aqueous solution

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

origen biológico

mouse

Nivel de calidad

conjugado

unconjugated

forma del anticuerpo

purified immunoglobulin

tipo de anticuerpo

primary antibodies

clon

1696, monoclonal

formulario

buffered aqueous solution

reactividad de especies

human immunodeficiency virus

concentración

1 mg/mL

técnicas

FUNC: suitable
immunoblotting: suitable
indirect ELISA: suitable

isotipo

IgG1

Condiciones de envío

wet ice

temp. de almacenamiento

2-8°C

modificación del objetivo postraduccional

unmodified

Descripción general

Human immunodeficiency virus (HIV) protease expressed in the 5′ end of pol gene is part of gag-pol polyprotein. HIV protease has 99 amino acids. The monomers of the protein are inactive; homodimers of the protein are enzymatically active. The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.

Inmunógeno

Bacterially expressed full-length HIV-1 protease

Acciones bioquímicas o fisiológicas

HIV protease is an aspartyl protease which is essential for cleavage of viral progenitor polyprotein. Protease activity is critically essential for the life cycle of the virus. HIV protease cleaves gag protein into three larger fragments p24, p17 and p7, which are the core structural protein and essential for RNA packaging. Protease also cleaves gag-pol fusion protein of the virion. The favourable cleavage site of HIV protease is N-terminal to proline, like phenylalanine-proline, tyrosine-proline, which is uncommon for mammalian proteases. The cleavage happens after the budding of the virion from the infected cell surface, transform into a mature infectious virus. Lack of protease results in immature and non-infectious viral particles. Inhibitors targeted to HIV protease is the recent advancement in the treatment of HIV infection.

Características y beneficios

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Forma física

Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

HIV-protease inhibitors
Flexner C
The New England Journal of Medicine, 338(18), 1281-1293 (1998)
Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
Kim EE, et al.
Journal of the American Chemical Society, 117(3), 1181-1182 (1995)
HIV protease: a novel chemotherapeutic target for AIDS
Huff JR
Journal of Medicinal Chemistry, 34(8), 2305-2314 (1991)
The mechanism of insulin resistance caused by HIV protease inhibitor therapy
Murata M, et al.
The Journal of Biological Chemistry, 275(27), 20251-20254 (2000)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico